Description
Factor XI Deficiency is a rare autosomal recessive disease, which is
the result of the mutation of the F11 located on chromosome 4. This
deficiency causes Hemophilia C. Factor XI is produced by the liver
and is part of a chain of clotting factor responsible for stopping
bleeding by forming a clot after an injury or surgery.

Treatment
Individuals are not given treatment for prevention. Rather treatment
depends on the invasive procedure that is undergone. People
undergoing surgery will be treated with fresh frozen plasma and will
continue to receive it 7-14 after surgery. Pregnant women that will
be undergoing cesarean section need fresh frozen plasma. However, it
is controversial whether plasma should be given prenataly to women
who will undergo vaginal deliveries. Though there is a high
incidence of postpartum hemorrhage there is the risk of exposure to
blood borne pathogens in the blood plasma. Factor replacement has
been used successfully with dental procedures and excessive
menstrual bleeding. It is further highly recommended that
individuals receiving fresh frozen plasma with surgery should be
immunized for Hepatitis A and B viruses.

Testing
Diagnosis: via blood test to determine the level of Factor XI level
in the blood and to ascertain if there is a specific PTA genetic
mutation.